<DOC>
	<DOCNO>NCT00519090</DOCNO>
	<brief_summary>In study , efficacy safety nilotinib 400 mg twice daily , compare imatinib 400 mg twice daily patient suboptimal response imatinib Philadelphia chromosome-positive ( Ph+ ) Chronic Myelogenous Leukemia chronic phase ( CML-CP ) .</brief_summary>
	<brief_title>Nilotinib v Imatinib Adult Patients With Philadelphia ( Ph+ ) Chronic Myelogenous Leukemia Chronic Phase ( CML-CP )</brief_title>
	<detailed_description>This trial evaluate CCyR rate 12 month nilotinib therapy compare imatinib treatment patient suboptimal response imatinib . The patient stratify prior duration initial imatinib treatment , randomize receive either 400 mg/twice daily continuous nilotinib imatinib treatment . The first stratum patient treat imatinib = 6 &lt; 12 month least minimal cytogenetic , partial cytogenetic response ; second stratum patient treat imatinib = 12 month &lt; 18 month partial cytogenetic response ( PCyR ) , CCyR .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Inclusion criterion : Diagnosis Philadelphia chromosome positive chronic myelogenous leukemia chronic phase . Patients suboptimal cytogenetic response dose 400 mg imatinib ( first line therapy ) define : 6 &lt; 12 month treatment 36 95 % Ph+ metaphases , 12 &lt; 18 month treatment 1 35 % Ph+ metaphases ( Standard cytogenetics , FISH [ fluorescence situ hybridization ] analysis allow ) . Exclusion criterion : Patient receive 18 month imatinib therapy Patients achieve partial complete cytogenetic response lose response prior enter study . Prior treatment great 400 mg/day imatinib . Uncontrolled significant cardiovascular disease . Severe uncontrolled medical condition ( i.e . uncontrolled diabetes , active uncontrolled infection ) . Use therapeutic coumarin derivative ( i.e. , warfarin , acenocoumarol , phenprocoumon ) Currently take certain medication could affect rhythm heart . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>leukemia</keyword>
	<keyword>bone marrow</keyword>
	<keyword>leukemia symptom</keyword>
	<keyword>cml</keyword>
	<keyword>complete blood count</keyword>
	<keyword>lymphocyte</keyword>
	<keyword>blood cancer</keyword>
	<keyword>leukocyte</keyword>
	<keyword>chronic leukemia</keyword>
	<keyword>bone marrow biopsy</keyword>
	<keyword>leukemia research</keyword>
	<keyword>leukemia cell</keyword>
	<keyword>bone marrow disease</keyword>
	<keyword>chronic myeloid leukemia</keyword>
	<keyword>blood cancer symptom</keyword>
	<keyword>white blood cell disease</keyword>
	<keyword>chronic myelogenous leukemia</keyword>
	<keyword>leukemia treatment</keyword>
	<keyword>leukemia fact</keyword>
	<keyword>leucemia</keyword>
	<keyword>fact leukemia</keyword>
	<keyword>myelogenous leukemia</keyword>
	<keyword>newly diagnose CML</keyword>
	<keyword>suboptimal response</keyword>
	<keyword>Philadelphia chromosome positive ( Ph+ )</keyword>
	<keyword>chronic myelogenous leukemia chronic phase ( CML-CP )</keyword>
</DOC>